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Abstract
Background: MicroRNAs (miRNAs) are important regulators of cellular function and have been associated with
both aging and cancer, but the impact of chemotherapy on age-related miRNAs has barely been studied.
Our aim was to examine whether chemotherapy accelerates the aging process in elderly breast cancer patients
using miRNA expression profiling.
Methods: We monitored age-related miRNAs in blood of women, aged 70 or older, receiving adjuvant
chemotherapy (docetaxel and cyclophosphamide, TC) for invasive breast cancer (chemo group, CTG, n = 46). A
control group of older breast cancer patients without chemotherapy was included for comparison (control group,
CG, n = 43). All patients underwent geriatric assessment at inclusion (T0), after 3 months (T1) and 1 year (T2).
Moreover, we analysed the serum expression of nine age-related miRNAs (miR-20a, miR-30b, miR-34a, miR-106b,
miR-191, miR-301a, miR-320b, miR-374a, miR-378a) at each timepoint.
Results: Except for miR-106b, which behaved slightly different in CTG compared to CG, all miRNAs showed
moderate fluctuations during the study course with no significant differences between groups. Several age-related
miRNAs correlated with clinical frailty (miR-106b, miR-191, miR-301a, miR-320b, miR-374a), as well as with other
biomarkers of aging, particularly Interleukin-6 (IL-6) and Monocyte Chemoattractant Protein-1 (MCP-1) (miR-106b,
miR-301a, miR-374a-5p, miR-378a-3p). Moreover, based on their ‘aging miRNA’ profiles, patients clustered into two
distinct groups exhibiting significantly different results for several biological/clinical aging parameters.
Conclusions: These results further corroborate our earlier report, stating that adjuvant TC chemotherapy does not
significantly boost aging progression in elderly breast cancer patients. Our findings also endorsed specific age-
related miRNAs as promising aging/frailty biomarkers in oncogeriatric populations.
Trial registration: ClinicalTrials.gov, NCT00849758. Registered on 20 February 2009. This clinical trial was registered
prospectively.
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Background
(Breast) cancer treatment in the elderly represents a
major challenge in clinical oncology. Despite their im-
portant representation within the overall breast cancer
(BC) population, older women are often excluded from
standard BC medical treatment regimens, or are offered
less aggressive (and possibly less effective) therapies.
This is attributable to concerns about increased risk of
side effects, as well as decreased medical fitness of older
cancer patients, either perceived or assumed by subject-
ive clinical evaluation. According to international guide-
lines for patient management in geriatric oncology, it is
not justified to base treatment choices on chronological
age only [1]. In addition to the already available geriatric
assessment (GA) tools, new clinical and biological tools,
including circulating biomarkers of aging, are currently
being developed to better assess global health and
individualize therapeutic strategies [2–8].
Besides the risks that chemotherapy imposes to frail
patients, the impact that it may have on the aging
process of more fit elderly patients is still not well
understood. Based on the observation of cellular senes-
cence induced by cytotoxic agents (including anticancer
molecules) [9], researchers have been investigating pos-
sible effects of chemotherapy on aging progression. Data
obtained from follow-up studies have shown that adult
survivors of childhood cancers develop degenerative dis-
eases (typical of old age) earlier in life and with a higher
incidence compared to the general population [10].
Chemotherapy-induced aging and frailty are assumed to
be caused, among other factors, by production of free
radical intermediates, persistent DNA damage not coun-
terbalanced by adequate DNA repair mechanisms, and/
or senescence triggered by telomere instability [11]. In a
small cohort of patients with head and neck cancer,
telomeres of peripheral blood mononuclear cells were
reported to be severely shortened after combined
chemo-radiotherapy, especially in older patients [12].
Similar results were also obtained in patients who
underwent chemotherapy for BC [13] and non-Hodgkin
lymphoma [14].
To investigate the hypothesized acceleration of the aging
process by cancer treatment we have recently conducted a
prospective clinical study in older (70+) BC patients, that
monitored the evolution during adjuvant chemotherapy of
both clinical aging parameters (GA) and various biological
markers described in the literature as potential biomarkers
of aging. This biomarker panel included leukocyte telo-
mere length, the inflammation-related plasma cytokines/
chemokines IL-6, Tumor Necrosis Factor-alpha (TNFα),
Interleukin-10 (IL-10), Regulated on Activation, Normal
T-Cell Expressed and Secreted (RANTES)/ C-C motif
chemokine-5 (CCL5) and MCP-1/C-C motif chemokine-2
(CCL2) as markers of ‘inflammaging’, and the
aging-related protein Insulin-like Growth Factor-1 (IGF-1)
[5, 15–23].
Clinical and biomarker assessments were accom-
plished at three different time points, i.e. prior to initi-
ation of chemotherapy, after 3 months (last cycle of
chemotherapy) and after 1 year. The study comprised a
cohort of BC patients receiving docetaxel/cyclophospha-
mide treatment and a control cohort receiving only hor-
mone treatment. The results of the above-mentioned
work have been published recently [24].
In the present study, we attempted to further expand
our insight into the potential connections between adju-
vant chemotherapy and biological aging, by analysing
the behaviour of circulating aging-related miRNAs previ-
ously identified by our group [25].
Indeed, in addition to the above-mentioned aging bio-
markers, several miRNAs have also been implicated in
the aging process [25, 26]. MiRNAs are small molecules
(18–22 nucleotides) belonging to the wider class of
non-coding RNAs, which exert non-permanent epigen-
etic functions via the post-transcriptional regulation of
gene expression [27]. Mutations and/or altered expres-
sion of miRNAs have been associated with several
pathological conditions, including cancer [28–40]. More-
over, miRNAs may play a role in the aging process, as
some of them are part of molecular pathways that regu-
late cellular senescence. The expression of miR-34a, for
instance, is induced by p53, and high levels of this
miRNA result in growth arrest [41, 42]. This miRNA has
also been positively associated with myocardial aging. Its
primary target is the longevity-associated deacetylase
SIRT-1 [43] that regulates chromatin remodelling, stress
responses, DNA repair and insulin regulation.
Several of the miRNAs reported in the literature to be
associated with aging have also been found to be over-
or underexpressed in cancer patients [29, 34, 35, 39, 40].
To identify plasma miRNAs with aging biomarker potential
within a cancer population, we have first carried out a plasma
miRNA screening study involving young and older BC pa-
tients [25]. From this pilot study, we have established a panel
of miRNAs that were found to be differentially expressed ac-
cording to age among BC patients: miR-20a, miR-30b,
miR-34a, miR-106b, miR-191, miR-301a, miR-320b, miR374-
aand miR-378a-3p. Here, we have examined the quantitative




From 2009 to 2012, women at least 70 years old who
were affected by locally-advanced, non-metastatic BC
and eligible for adjuvant systemic chemotherapy were
enrolled at 5 hospitals in Belgium, henceforth referred to
as “chemotherapy group” (CTG). This group consisted
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originally of 57 patients, and miRNA data were available
at the 3 time points in 46 patients.
In parallel, a comparable series of patients, not eligible
for systemic chemotherapy, but only for endocrine treat-
ment were included as a “control group” (CG) [24]. This
group consisted originally of 52 patients, and miRNA
data were available at the 3 time points in 43 patients.
Patient and tumor characteristics of the study cohort
can be found in Table 1 of our previous publication [24].
The antineoplastic therapy administered to the CTG
consisted of docetaxel at a dose of 75 mg/m2 plus cyclo-
phosphamide at 600 mg/m2 every 3 weeks for a total of
4 cycles (TC scheme) [44] . G-CSF (granulocyte-colony
stimulating factor) was administered at each cycle, ac-
cording to the National Comprehensive Cancer Network
(NCCN) guidelines [45]. The planned adjuvant treat-
ment also included an aromatase inhibitor (to be admin-
istered after chemotherapy completion) in case of
hormone-sensitive tumors, and trastuzumab administra-
tion in case of Her2 positive tumors.
Conversely, patients in the CG received an aromatase
inhibitor as sole medical treatment. In both groups, radi-
ation therapy was either or not administered according
to institutional practice. Enrolment took place after
breast surgery. Blood samples were collected at three
time points: T0: between 3 and 6 weeks after surgery, al-
ways before the first cycle of chemotherapy; T1:
3 months after inclusion (in principle the day of the
fourth and last cycle of chemotherapy for patients in the
CTG); T2: 1 year after inclusion. At each time point, pa-
tients also underwent clinical geriatric evaluation.
This study was approved by the local ethics commit-
tees of Clinique Sainte Elisabeth (Namur), Imelda Hos-
pital (Bonheiden), Jessa Hospital (Hasselt), Zol
Ziekenhuis Oost-Limburg (Genk), Jules Bordet Institute
(Brussels), and by the University Hospitals Leuven
central ethics committee. All patients signed a
written informed consent in accordance to the
Helsinki Declaration. This clinical trial was regis-
tered prospectively.
This article adheres to CONSORT guidelines, where
applicable.
Clinical geriatric evaluation
Detailed information on GA tools and results of clinical
evaluation accomplished at the different time points
have been extensively documented in our primary study
on aging biomarkers and chemotherapy [24]. Briefly, pa-
tients were screened at baseline with the G8 screening
tool and the Flemish version of the Triage Risk Screen-
ing Tool (fTRST), and social data were collected (age,
living situation, marital status and educational level).
At each time point also a geriatric assessment (GA)
was performed, as well as a frailty assessment with Bal-
ducci Frailty score and Leuven Oncogeriatric Frailty
Score (LOFS) [5]. Moreover, we assessed performance
status according to the Eastern Cooperative Oncology
Group - Performance Status (ECOG-PS), and quality of
life (QoL) using the EORTC QLQ-C30 questionnaire.
At both T1 and T2, adverse events (using the CTCAE
v4.0 classification) and unexpected hospitalizations were
also monitored.
Endpoints
Our primary endpoint was to evaluate whether
aging-related miRNAs changed during the study period
and, if so, whether relevant differences could be detected
over time between CTG and CG.
As secondary endpoints, we also assessed (i) potential
correlations of miRNAs measured at inclusion (T0) with
Table 1 Evolution of microRNAs over time in CTG
MicroRNAa Inclusion versus 3 months Inclusion versus 1 year Study arm by time interactionc
Mean differenceb 95%CI p-value Mean differenceb 95%CI p-value p-value
miR-20a −0.52 (−1.05, 0.01) 0.0537 −0.22 (−0.75, 0.31) 0.4042 0.0898
miR-30b −0.39 (−0.60, − 0.18) 0.0003 −0.22 (− 0.42, − 0.02) 0.0319 0.0987
miR-34a 0.76 (0.25, 1.26) 0.0039 0.60 (0.18, 1.01) 0.0054 0.9884
miR-106b 0.03 (−0.17, 0.23) 0.7671 0.18 (0.00, 0.37) 0.0497 0.0240
miR-191 −0.09 (− 0.32, 0.15) 0.4669 − 0.27 (− 0.51, − 0.03) 0.0272 0.2045
miR-301a − 0.11 (− 0.30, 0.09) 0.2673 −0.15 (− 0.39, 0.09) 0.2280 0.6222
miR-320b 0.10 (−0.15, 0.34) 0.4377 −0.01 (−0.22, 0.20) 0.9337 0.4120
miR-374a −0.28 (−0.55, − 0.01) 0.0394 −0.12 (− 0.38, 0.13) 0.3470 0.2125
miR-378a −0.02 (−0.21, 0.17) 0.8168 0.01 (−0.15, 0.16) 0.9413 0.6858
amiR-34a, miR-320b and miR-378a were previously shown to increase with aging; miR-20a, miR-30b, miR-106b, miR-191, miR-301a and miR-374a were previously
shown to decrease with aging
bmiRNA normalized relative quantities were log2-transformed prior to statistical analysis; log2 values were subtracted to calculate mean differences between
time points
cSignificant interaction indicates different miRNA evolution in CTG as compared to CG
p-values < 0.05 are marked in bold
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chronological age, clinical geriatric assessment parame-
ters and aging biomarkers reported in our primary paper
[24]; (ii) whether miRNAs at inclusion had a predictive
value towards acute and/or irreversible decline in func-
tionality and in QoL; (iii) whether miRNAs at inclusion
predicted toxicity and unexpected hospitalizations dur-
ing and after chemotherapy; (iv) correlation patterns be-
tween the 9 miRNAs and possible formation of patient
clusters based on miRNA expression profiles.
Blood sample collection and processing
At each time point, 4-mL whole blood specimens were
collected from each patient in BD Vacutainer SST II Ad-
vance serum tubes. After incubation at room
temperature for 20 to 60 min, the blood samples were
centrifuged at 1300×g for 10 min at 4 °C and superna-
tants (serum) were aliquoted and stored at − 80 °C.
Aging biomarker analysis
Methodology and results of biomarker analyses (i.e.
leukocyte telomere length, circulating IL-6, IL-10, TNFα,
RANTES/CCL5, MCP-1/CCL2 and IGF-1) performed at
the 3 time points were described in detail in our previ-
ous publication [24].
Isolation of miRNAs from serum
For each sample, 250 μL of serum were thawed on ice
and then centrifuged at 3000 x g for 5 min to remove
debris. To 200 μL of supernatant, 1 μg of carrier MS2
RNA (Roche) was added in order to stabilize RNA dur-
ing extraction and cDNA synthesis. Moreover, 1 μL of
the synthetic RNA spike-in UniSp6 was added to allow
evaluation of the efficiency and uniformity of the entire
RNA extraction/cDNA synthesis procedure. Then, miR-
NAs were isolated with the miRCURY™ RNA Isolation
Kit–Biofluids (Exiqon), following the manufacturer’s in-
structions. Spin columns were finally eluted twice with
25 μL DNase/RNase-free water each time. Both eluates
were pooled and stored at − 80 °C.
cDNA synthesis and qPCR
On each purified miRNA sample, cDNA synthesis was
performed in duplicate. 2 μL of miRNA extract were proc-
essed using the Universal cDNA synthesis kit II (Exiqon),
according to the manufacturer’s instructions. cDNA sam-
ples were stored at − 80 °C until PCR analysis.
Measurement of relative amounts of transcripts was car-
ried out by real-time qPCR analysis using Pick-&-Mix
microRNA PCR panels (96 well Ready-to-Use custom
plates) with Exilent SYBR® Green Master Mix (Exiqon).
For each RNA sample, both duplicate cDNAs were
assessed in a single plate. Every plate included primers for:
5 reference miRNAs (hsa-miR-23a-3p, hsa-miR-29a-3p,
hsa-miR-29c-3p, hsa-miR-140-3p, hsa-miR-484, further
referred to as miR-23a, miR-29a, miR-29c, miR-140 and
miR-484) used for data normalization, the 9 aging-related
miRNAs of interest selected for the study (see below) and
the synthetic spike-in UniSp6 to allow evaluation of
miRNA extraction/reverse transcription efficiency. The 9
aging miRNAs included 3 that were previously shown to
increase with aging (hsa-miR-34a-5p, hsa-miR-320b and
hsa-miR-378a-3p, further referred to as miR-34a,
miR-320b and miR-378a), and 6 that previously showed
negative association with aging (hsa-miR-20a-3p,
hsa-miR-30b-5p, hsa-miR-106b-5p, hsa-miR-191-5p,
hsa-miR-301a-3p and hsa-miR-374a-5p, further referred
to as miR-20a, miR-30b, miR-106b, miR-191, miR-301a
and miR-374a) [25]. All plates additionally included the
interplate calibrator UniSp3, in order to allow detection of
global amplification differences due to inter-run variation.
Assays were carried out following the manufacturer’s
specifications. Briefly, cDNA was diluted 50x in nuclease
-free water and mixed with an equal volume of 2x Exi-
lent SYBR Green master mix (Exiqon). Final reaction
volume was 10 μL. Plates were run on a LightCycler 480
(LC480, Roche) instrument applying the following ther-
mal cycling protocol: activation step (10 min at 95 °C);
45 amplification cycles (10 s at 95 °C, 1 min at 60 °C,
ramp rate 1,6 °C/s); melting curve analysis.
Quality control and processing of PCR data
As haemolysis can alter the relative amounts of different
serum miRNAs through the release of intracellular miR-
NAs from erythrocytes, a quality control was performed
using the miR-451/miR-23a-3p hemolysis test [46]. Fol-
lowing qPCR analysis of the expression of miR-451
(highly expressed in erythrocytes) and miR-23a-3p (sta-
bly expessed in biofluids), all samples with a Delta Cp
value (Cp miR-451 minus Cp miR-23a-3p) higher than 5
were excluded from further analysis. Samples with bor-
derline results (Delta Cp between 4 and 5) were
double-checked for haemolysis using a second method.
Thawed serum samples were briefly spun down to re-
move debris, and then the absorbance spectrum was
assessed on a Nanodrop ND-1000. Samples showing an
apparent absorption peak at 415 nm (the hemoglobin
absorption maximum) were excluded from the study.
The qPCR data were processed using the MultiD GenEx
software. We visually inspected expression profiles of all
miRNAs and the UniSp6 across all samples on a bidi-
mensional line plot. Samples with a clearly deviating ex-
pression for the entire miRNA panel were excluded
from further analysis. Normalization was performed
using the 5 reference transcripts miR-23a-3p, miR
-29a-3p, miR-29c-3p, miR-140-3p and miR-484. These
were validated in our previous paper [25] as suitable ref-
erence miRNAs for serum/plasma samples by the algo-
rithm tools GeNorm and NormFinder and were now
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again confirmed to be stably expressed across all serum
samples. Technical repeats (duplicate cDNAs per sam-
ple) were averaged and finally, all values were con-
verted to relative quantities and then log-transformed
(Log2 scale).
Statistical analysis
For the primary endpoint, miRNAs were modelled as re-
sponse variables in linear models for repeated measures
with time, group and their interaction as explanatory
variables. An unstructured residual covariance matrix
was modelled to account for clustering.
The evolution over time in the CTG was assessed by
estimating the change in miRNA level between inclusion
(T0) and 3 months (T1) and between inclusion (T0) and
12 months (T2). Results were presented by the mean
change between time points with 95% confidence inter-
val (CI). The difference in evolution between chemother-
apy and control patients was assessed by a test for group
by time interaction.
For the secondary endpoints, Spearman correlations
were used for studying univariable association of miRNAs
with continuous or ordinal variables. Kruskal-Wallis tests
were used to compare miRNA levels between more than 2
groups, and Mann-Whitney U tests for comparisons be-
tween two groups. Multivariable models: a backward se-
lection procedure was applied for selecting a set of
miRNA as independent predictors of response variables
(age, clinical aging parameters and aging biomarkers). Lin-
ear regression was used for continuous variables, logistic
regression for binary variables, and proportional odds
models for ordinal variables. Mann-Whitney U tests were
used for comparing miRNA levels between patients with and
without decline in functionality, unexpected hospitalization
or grade II-III-IV toxicity.
The association between the miRNAs were studied by
means of Pearson correlations. To identify groups (clus-
ters) of patients with similar miRNA profiles, a disjoint
cluster analysis was performed based on minimizing the
sum of squared (euclidian) distances from the cluster
means; miRNA values were standardized for this ana-
lysis. To decide upon the number of clusters, we took
into account the pseudo F statistic (larger means better
fit) and the number of patients per cluster. The SAS
procedure FASTCLUS was used for this analysis. Ana-
lyses were performed for data measured at inclusion.
Mann-Whitney U tests were used for comparing pa-
tients within two clusters on ordinal or continuous vari-
ables. Fisher exact tests were used for comparing
clusters on categorical or binary outcomes (decline,
hospitalization, toxicity).
All tests were two sided, and a 5% significance level
was considered for all tests.
All analyses have been performed using SAS software,
version 9.4 of the SAS System for Windows. Copyright
© 2002 SAS Institute Inc. SAS and all other SAS Insti-
tute Inc. product or service names are registered trade-
marks or trademarks of SAS Institute Inc., Cary, NC,
USA.
Figures were performed using using GraphPad Prism
version 6.00 for Windows, GraphPad Software, La Jolla,
CA, USA.
Results
Evolution of aging miRNAs over time during BC
treatment
For each miRNA, time evolution in both CTG and CG
is shown in Fig. 1 and the corresponding statistics are
summarized in Table 1. Several miRNAs showed signifi-
cant changes in patients of CTG during the course of
the study: miR-34a was increased at T1 (p = 0.0039)
while miR-30b and miR-374a were decreased at T1 (p =
0.0003 and 0.0394, respectively). For miR-374a, these
changes appeared to be transient: the initial miRNA
levels measured at inclusion (T0) were restored after
1 year (T2). In contrast, the observed changes of
miR-30b and miR34a still persisted after 1 year, albeit
somewhat less pronounced (mean differences were −
0.22 at T2 versus − 0.39 at T1 for miR-30b and 0.60 at
T2 versus 0.76 at T1 for miR-34a). However, for none of
these three miRNAs, a significant difference in evolution
over time could be demonstrated when comparing CTG
with CG, as indicated by the lack of a statistically signifi-
cant group by time interaction. Plasma levels of
miR-106b and miR-191 were found to be slightly in-
creased (p = 0.0497), respectively decreased (p = 0.0272)
in CTG at T2 but not at T1. Moreover, a significant
group by time interaction (p = 0.024) for miR-106b may
point to a different evolution of this miRNA in CTG ver-
sus CG. No significant modifications were observed for
the other miRNAs (miR-20a, miR-301a, miR-320b,
miR-374a, miR-378a) during the time course of the study
(Fig. 1, Table 1). Overall, the observed differences over
time did not appear to depend on the type of administered
treatment, hinting toward the lack of an effect of chemo-
therapy on aging in the analysed population. Of note, 3
miRNAs (miR-20a, miR-301a, miR-320b) were signifi-
cantly different at baseline (in the direction of increased
aging) in CG compared to CTG, corresponding to the fact
that clinical aging was also slightly more pronounced in
CG (see Table 3 from our recent publication [24]).
Association of aging miRNAs with patient’s chronological
age
In initial univariable analyses, patient age at inclusion,
strongly tended to be associated with several previously
identified aging related miRNAs [25] measured at T0
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(i.e. miR-30b, miR-374a, miR-106b, miR-301a, miR-320b),
even within this ‘purely elderly population’ (Table 2).
In a next step, a backward multivariable model selec-
tion procedure was applied, resulting in a model with
miR-301a as the only independent explanatory variable
for age. The model revealed a negative association be-
tween miRNA-301a and age: higher age is associated
with lower miR-301a levels (p = 0.0006) (Table 3), which
is in accordance with our previous findings [25].
Association of miRNAs with clinical aging
Next, we investigated whether the ‘aging miRNAs’, mea-
sured at inclusion, correlated with the patient’s clinical
aging status, also assessed at T0.
The output of the univariable analysis (Table 2) re-
ported a positive correlation of miR-191, miR-301a and
miR-374a with LOFS score. In the subsequent
multivariable model (Table 3), however, miR-320b and
miR-374a emerged as independent predictors for LOFS,
with higher LOFS scores being associated with higher
miR374a and lower miR-320b levels. Note that different
statistical techniques used for univariable and multivari-
able analysis may account for the apparent discrepancy
in miRNAs arising as significant predictors.
Conversely, none of the miRNAs showed an associ-
ation with the Balducci frailty score as ordinal outcome:
the preliminary observed difference of miR-301a levels
between the 3 categories fit, vulnerable and frail (p =
0.037) (Table 2) was not confirmed in the multivariable
analysis (Table 3).
Although none of the miRNAs showed a significant
individual association with G8 total score (Table 2), 4
miRNAs (miR-106b, miR-191, miR-320b, and miR-374a)
resulted as independent predictors of total G8 from the
Fig. 1 Time evolution of aging miRNAs in ChG and CoG
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backward multivariable model selection procedure
(Table 3). This may point out toward a coordinated set
of molecular changes reflecting the parameters assessed
by this score. Concerning fTRST, which returns a
higher score (scale 0–6) with increasing frailty, a
negative correlation was observed for miR-301a, which
was confirmed by the multivariable model selection
(Tables 2 and 3).
Association of miRNAs at inclusion with other aging
biomarkers
We also examined possible correlations between the
‘aging miRNAs’ and other aging biomarkers measured at
T0.
Mean leukocyte telomere length (T/S ratio) was nega-
tively correlated with miR-320b (Table 4), which was
confirmed to be the only explanatory variable in the
multivariable model selection (Table 3). Two other miR-
NAs, miR-34a and miR-106b, were borderline significant
in the univariable analysis (Table 4), but were not
retained in the multivariable model selection procedure
(Table 3).
In univariable analysis, 5 miRNAs were found to be
negatively correlated with IL-6, a cytokine well known to
be increased during aging, particularly in frail individ-
uals. Those were miR-30b, miR-106b, miR-191, miR301a
and miR-374a. Conversely, miR-378a-3p showed a posi-
tive correlation with IL-6 (Table 4). These correlation
trends are in line with our previous findings that
miR-30b, miR-106b, miR-191 and miR-374 are all de-
creased, while miR-378a is increased, in elderly versus
young patients, and with the widely documented
age-related increase in plasma IL-6 levels [15, 16]. Of
these 6 miRNAs that were significantly associated with
IL-6, 3 resulted as significant independent predictors of
IL-6 in the multivariable model: miR-106b, miR-374a
and miR-378a (Table 3). Furthermore, TNF-α and
MCP-1, which are also known to gradually increase in
plasma during aging, showed pronounced associations
with several ‘aging miRNAs’. As expected, negative asso-
ciations were found for miRNAs showing decreased ex-
pression with higher age (miR-106b, miR-191, miR-301a,
miR-374a) whereas positive associations were found for
miRNAs showing increased expression with higher age
(miR-378a, miR-320b) (Table 3). Higher miR-320b values






Calendar age a miR-301a −2.371 (−3.700; −1.042) 0.0006
BALDUCCI b – – – –
LOFS a miR-320b − 0.623 (− 1.187; − 0.059) 0.0308
miR-374a 0.940 (0.396; 1.483) 0.0009
G8-total a miR-106b −1.145 (−2.082; − 0.209) 0.0171
miR-191 − 1.461 (− 2.478; − 0.444) 0.0054
miR-320b − 0.776 (− 1.461; − 0.092) 0.0266
miR-374a 1.209 (0.436; 1.982) 0.0026
fTRST b miR-301a 0.487 (0.254; 0.934) 0.0302
Telomere length a miR-320b −0.095 (− 0.170; − 0.021) 0.0131
IL-6 a miR-106b −0.338 (−0.603; − 0.072) 0.0133
miR-374a − 0.294 (− 0.497; − 0.090) 0.0053
miR-378a 0.301 (0.011; 0.591) 0.0418
IL-10 a – – – –
IGF-1 a – – – –
TNFα a miR-320b 0.193 (0.040; 0.345) 0.0140
MCP-1 a miR-301a −0.180 (− 0.320; − 0.040) 0.0121
miR-378a 0.269 (0.098; 0.441) 0.0025
RANTES a miR-378a −0.390 (− 0.736; − 0.045) 0.0271
aContinuous variable; slope indicates mean change in response variable for a 1-unit increase of miRNA values. Slope > 0 indicates positive association; slope < 0
indicates inverse correlation
bOrdinal variable; odds ratio > 1 indicates increase in response variable with increased miRNA value (positive association); odds ratio < 1 indicates decrease in
response variable with increased miRNA value (negative association)
cmiR-34a, miR-320b and miR-378a were previously shown to increase with aging; miR-20a, miR-30b, miR-106b, miR-191, miR-301a and miR-374a were previously
shown to decrease with aging
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were confirmed to be associated with higher TNF-α
levels (p = 0.0140) in the subsequent multivariable selec-
tion model (Table 3). For MCP-1, the multivariable se-
lection model further corroborated miR-301a (p =
0.0121) and miR-378a (p = 0.0025) as independent ex-
planatory variables (Table 2). For the other plasma bio-
markers (i.e. IL-10, RANTES, IGF-1), no consistent
correlations were established in univariable and/or mul-
tivariable analyses (Tables 4 and 3).
Association of miRNAs with adverse effects of
chemotherapy: decline of functionality and QoL,
unexpected hospitalization and toxicity
In CTG, none of the individual miRNAs measured at in-
clusion (T0) was predictive of decline in functionality or
decline in QoL at 3 months (T1) or at 1 year (T2): initial
miRNA levels at T0 did not significantly differ between
patients who experienced a decline in functionality and/or
QoL during the course of the study and patients who did
not (all p ≥ 0.05). Also, in patients exhibiting a decline in
functionality and/or QoL at 3 months or at 1 year, miRNA
plasma levels at the corresponding time point were not
significantly altered (all p ≥ 0.05). Moreover, miRNAs
plasma level at inclusion neither predicted grade II-III-IV
toxicity at 3 months, nor unexpected hospitalization dur-
ing the whole time course (all p > 0.1) (results not shown).
Correlations and cluster analysis of the 9 miRNAs
We have also examined the interrelationship between
the 9 miRNAs included in the study; Table 5 summa-
rizes Spearman’s correlation coefficients and associated
p-values, based on miRNA measurements at inclusion.
As expected, strong correlations exist between several
miRNAs of the ‘aging miRNA’ panel, most particularly
miR-30b, miR-191, miR-301a and miR-374a. Accord-
ingly, a disjoint cluster analysis based on T0 miRNA
measurements, revealed two main patient clusters of
which one (cluster A) consistently scores lower on
miR-20a, miR-30b, miR-191, miR-301a and miR-374a
and higher on miR-378a compared to the other (cluster
B), which is consistent with an ‘older’ aging profile for
cluster A (Fig. 2). For the remaining miRNAs (miR-34a,
miR106b and miR-320b), differences between patient
clusters were either small or inconsistent, as shown in
Fig. 2. One patient did not fit either of both clusters and
was excluded from the cluster analysis.
In a next step, we compared both patient groups to
determine whether they also showed differences with
respect to aging biomarkers and/or clinical variables
at inclusion. Interestingly, patients from cluster A in-
deed exhibited significantly higher fTRST, IL-6, TNFα
and MCP-1 (Table 6), along with a higher mean age.
LOFS was also apparently decreased in these patients
(mean LOFS were 6.9 and 7.7 for clusters A and B,
respectively), but this difference was not statistically
significant (Table 6). Moreover, cluster A patients
showed a markedly higher tendency to experience a
decline in QoL during chemotherapy: 31.9% of cluster
A patients, versus only 7.4% of cluster B patients,
scored lower on QoL at 3 months (i.e. at the end of
chemotherapy treatment) as compared to inclusion
(p = 0.051).
Discussion
We have recently published a scientific article reporting
on the evolution of clinical and biological aging markers
in older BC patients receiving chemotherapy [24]. This
study demonstrated that adjuvant TC chemotherapy had
basically no impact on aging and frailty during a
one-year period; we only detected a modest and tempor-
ary alteration of clinical aging indicators, while estab-
lished aging biomarkers such as IL-6 did not show
significant fluctuations during the a one-year period.
Table 4 Univariable association of microRNAs with aging biomarkers at inclusion
MicroRNAa Telomere length IL-6 IL-10 IGF-1 TNFα MCP-1 RANTES
miR-20a −0.027 (0.8250) −0.131 (0.2208) − 0.141 (0.1979) −0.045 (0.6762) − 0.101 (0.3474) −0.045 (0.6743) − 0.052 (0.6273)
miR-30b −0.169 (0.1587) − 0.268 (0.0111) −0.166 (0.1291) 0.040 (0.7078) 0.049 (0.6479) −0.168 (0.1165) 0.057 (0.5987)
miR-34a −0.233 (0.0509) 0.057 (0.5962) −0.134 (0.2198) −0.104 (0.3306) 0.099 (0.3551) 0.184 (0.0835) −0.018 (0.8669)
miR-106b 0.228 (0.0559) −0.281 (0.0075) −0.096 (0.3841) 0.118 (0.2721) −0.310 (0.0031) − 0.288 (0.0062) 0.174 (0.1033)
miR-191 0.025 (0.8351) −0.304 (0.0038) −0.054 (0.6222) 0.015 (0.8891) −0.101 (0.3478) − 0.387 (0.0002) 0.074 (0.4878)
miR-301a −0.038 (0.7507) −0.340 (0.0011) − 0.070 (0.5236) 0.098 (0.3604) − 0.208 (0.0505) −0.328 (0.0017) 0.029 (0.7846)
miR-320b −0.234 (0.0492) 0.132 (0.2166) 0.171 (0.1181) −0.144 (0.1771) 0.396 (0.0001) 0.252 (0.0171) 0.040 (0.7115)
miR-374a −0.207 (0.0830) −0.337 (0.0012) − 0.248 (0.0221) 0.0003 (0.9777) − 0.024 (0.8250) −0.231 (0.0294) 0.192 (0.0713
miR-378a 0.018 (0.8842) 0.302 (0.0040) 0.153 (0.1620) −0.015 0.8866) 0.151 (0.1568) 0.295 (0.0051) −0.222 (0.0365)
In each cell are displayed the Spearman’s correlation coefficient, and according p-value in parentheses
p-values < 0.05 are marked in bold
amiR-34a, miR-320b and miR-378a were previously shown to increase with aging; miR-20a, miR-30b, miR-106b, miR-191, miR-301a and miR-374a were previously
shown to decrease with aging
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Aiming to corroborate these findings with additional
aging biomarkers, we decided to analyse, on the same
patient cohort, a panel of 9 miRNAs that were clearly
differentially expressed in elderly BC patients compared
to their younger counterparts in a previous exploratory
miRNA pilot study also carried out by our group [25].
This panel included miR-34a, miR-320b and miR378a,
which were previously found to be positively correlated
with age, and miR-20a, miR-30b, miR-106b, miR-191,
miR-301a and miR-374a, which previously showed nega-
tive associations with age.
We have found that several of these ‘aging miRNAs’
changed during the course of the study, but these
changes seemed rather transient and, most importantly,
no striking differences in miRNA evolution between
CTG and CG were revealed. Although an apparent dis-
crepancy between CTG and CG was noted for
miR-106b, the relevance of this observation can be ques-
tioned since the statistical significance was only mod-
estly persuasive and the direction of the change is not in
line with logic expectancies: given the previously estab-
lished negative correlation of miR-106b with age, one
would rather expect a decrease of miR-106b in
chemotherapy-treated patients. Thus, the present study
basically supports our previous statement that chemo-
therapy treatment is not associated with marked acceler-
ation of the aging process in elderly BC patients.
Besides this primary research question, we have also
further explored the relationships existing between the 9
selected ‘aging miRNAs’ and other parameters reflecting
the patient’s clinical and biological age. In line with our
previous findings, the present results show a decrease of
miR-301a with calendar age at inclusion. Four other
miRNAs of the panel, namely miR-30b, miR-106b,
miR-320b and miR-374a-5p, showed trends consistent
with our pilot data, but were not retained as independ-
ent explanatory variables for age in a multivariable
model, probably because of the small age range of this
study cohort (all ≥70).
Of relevance, miR-320b and miR-374a, which we pre-
viously found to be associated only with chronological
age, now showed a clear correlation with frailty (LOFS)
as well. Frail patients, scoring lower on the LOFS scale,
exhibited higher miR-320b and lower miR-374a levels,
as could be anticipated from the respectively positive
and negative correlations of these miRNAs with age.
Thus, these two miRNAs that evolve oppositely with
aging are actually also oppositely correlated with LOFS.
It should be noted that the basic Balducci frailty score,
unlike the more refined LOFS, did not show significant
associations with any of the 9 miRNAs in multivariable
analysis. For the G8 screening tool, scored at inclusion
and yielding a lower score with increasing frailty, 4 miR-
NAs of the aging panel (i.e. miR-106b, miR-191,
miR-320b and miR-374a) were identified as independent
predictors in the multivariable model selection. This
finding should, however, be interpreted with caution,
since 2 of these miRNAs (miR-106a and miR-191) were
correlated in the opposite direction as expected and
none of the four miRNAs showed a significant correl-
ation with G8 score in univariable analysis. For the
fTRST, yielding a higher score with increasing frailty, we
found a consistent negative association with miR-301a,
which is in full agreement with the age-related decrease
of this miRNA [25]. Thus, nearly all associations found
are consistent with the known age-related trends. Over-
all, these data are suggestive of a link between the aging
miRNAs and clinical frailty, whereas our previous
miRNA study only uncovered strong associations of the
9 miRNAs with chronological age but not with frailty
[25]. The larger number of patients included in the
present study probably afforded a greater statistical
power, allowing detection of biological/clinical correla-
tions that remained unrevealed in our initial miRNA
pilot study.
With regard to the correlations between the aging
miRNA panel and other biomarkers of aging, 6 of the se-
lected miRNAs (though 3 of them failed to reach statis-
tical significance in the multivariable analysis), correlated
with circulating levels of IL-6, a well-known aging bio-
marker [24] that we previously also found to be predictive
of frailty [5]. Moreover, lower mean leukocyte telomere
length, a well-described hallmark of biological aging, and
increased plasma TNFα were both associated with higher
miR-320b levels. This is once more in accordance with the
age-related increase in miR-320b, as previously reported
[25]. Finally, the plasma inflammatory chemokine MCP-1,
previously reported to increase with aging [5], was
Fig. 2 Different aging miRNA expression profile in patient clusters A
and B. Significant differences (p < 0.001) are indicated with
an asterisk
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positively correlated with miR-378a, which also increases
with age, and negatively correlated with miR-301a, which
decreases with age.
When studying interconnections between the 9 miR-
NAs, we found that patients actually clustered into two
major distinct subgroups with different ‘aging miRNA’ ex-
pression profiles: patients from one cluster showed signifi-
cantly lower expression of miR-30b, miR-191, miR-301a
and miR-374a and higher expression of miR-378a, as com-
pared to the other cluster, which is consistent with an
‘older’ miRNA profile. In perfect agreement, these patients
exhibited increased IL-6, TNFα, MCP-1 and also signifi-
cantly higher fTRST and a markedly higher propensity to-
wards decline in functionality during chemotherapy
treatment. Apparently, aging miRNA-based patient clus-
tering actually goes along with signs of different biological
and clinical age between clusters.
Taken together, our findings point to marked correla-
tions of (1°) chronological age with miR-301a, (2°)
biomarkers of aging with miR-106b, miR-301a,
miR-320b, miR-374a and miR-378a, and (3°) clinical
frailty with miR-320b and miR-374a. Experiments on
mice have previously suggested that miR-320b may be
involved in cardiac degeneration due to hyperglycemia,
as high levels of this miRNA are found in the diabetic
heart [47]. For miR-374a, however, this is the first study,
to the best of our knowledge, that reveals an association
with aging/frailty. We understand that our finding is
limited by its correlative nature, so that further research
is needed to assess whether a causative relationship links
these particular miRNAs and physical involution.
Some miRNAs previously found over- or under-
expressed with age, like miR-301a, or also with aging-
related health conditions (such as miR-34a and miR-20a)
[25, 26, 48] confirmed a trend in the same direction in
our present study, albeit without reaching a formal stat-
istical significance. One possible explanation could be
that there is no actual association between the examined
Table 6 Differences in biological and clinical aging markers between miRNA-based patient clusters at inclusion
Aging/frailty parameter Statistic Patient cluster A Patient cluster B p-value
Calendar age N 43 45
Mean ± SD 76.5 ± 5.2 73.8 ± 3.1 0.018
BALDUCCI
Fit n/N (%) 9/43 (20.9%) 12/44 (27.3%)
Vulnerable n/N (%) 12/43 (27.9%) 16/44 (36.4%)
Frail n/N (%) 22/43 (51.1%) 16/44 (36.4%) 0.378
LOFS N 42 44
Mean ± SD 6.9 ± 2.2 7.7 ± 1.7 0.119
G8-total N 43 45
Mean ± SD 14.1 ± 1.8 14.2 ± 2.1 0.571
fTRST N 36 30
Mean ± SD 2.3 ± 1.0 1.8 ± 0.9 0.046
Telomere length (T/S ratio) N 33 38
Mean ± SD 0.67 ± 0.17 0.74 ± 0.28 0.423
IL-6 a (pg/mL) N 43 45
Median (IQR) 4.3 (2.4; 6.4) 1.7 (1.0; 3.3) < 0.001
IL-10 (pg/mL) N 41 43
Mean ± SD 0.26 ± 0.25 0.25 ± 0.30 0.528
IGF-1 (pg/mL) N 43 45
Mean ± SD 73 ± 24 79 ± 24 0.308
TNFα (pg/mL) N 43 45
Median (IQR) 1.5 (0.9; 2.3) 1.2 (0.7; 1.6) 0.032
MCP-1 (pg/mL) N 43 45
Mean ± SD 197 ± 90 146 ± 57 < 0.001
RANTES (ng/mL) N 43 45
Mean ± SD 52 ± 42 64 ± 47 0.179
aFor IL-6 and TNFα, median and IQR was used instead of mean ± SD, to moderate the effect of outliers
p-values < 0.05 are marked in bold
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variables. However, since we are studying aging miR-
NAs in the context of elderly BC patients, we also
have to bear in mind the multifaceted nature of the
neoplastic process: indeed several miRNAs overex-
pressed during aging are underexpressed in patients
affected by neoplasms or vice versa. In fact, an asso-
ciation with cancer opposite to that observed during
aging has previously been demonstrated for miR-34a,
miR-106b, miR-191-5p, miR-301a, although some studies
generated conflicting results [29, 32, 34, 37–41, 49]. In par-
ticular, experiments on murine cell cultures revealed that
miR-34a, showing age-related increase, acts as an oncosup-
pressor molecule within the p-53 regulatory pathway [41].
Evidence of reduced levels of this miRNA in hepatocellular
carcinoma samples suggests that these functions may be
exerted in humans as well [35, 50]. On the other hand,
miR-106b and miR-20b, which both decrease at higher age,
belong to the so-called onco-miR cluster 17~ 92 and are
known to promote cancer growth by different mechanisms,
including the escape of senescence [28, 33, 36, 38, 40]. In
particular, miR-106b, which promotes cell cycle progression
by targeting the regulatory protein p21, is upregulated both
in cancer tissue and plasma of BC patients, and may be
responsible of chemoresistance in BC cell cultures [40].
Moreover, several mechanisms and molecular pathways
link cancer and aging in a not straightforwardly under-
standable way. Aging is a multifactorial process, in which
a major role is played by senescent cells. Cellular senes-
cence is a protective anti-cancer mechanism at young age,
arresting the cell cycle in case of acquired irreversible
DNA damage. However, the drawbacks of an accumula-
tion of senescent cells, most particularly the altered secre-
tion of inflammatory mediators, are mirrored at higher
age by nervous, cardiovascular, immune-endocrine degen-
eration and a higher susceptibility to cancer itself. Based
on all these data, we cannot exclude a confounding role of
the oncological pathology itself. It is thus important to
study aging biomarkers specifically in cancer populations,
and not only in non-cancer older populations.
The lack of convincing statistical significance for cer-
tain ‘aging miRNAs’ towards particular aging/frailty-re-
lated response variables may also be explained by the
notion that several miRNAs may act in a weak but
subtly coordinated fashion scarcely appreciable by con-
ventional statistics. As a consequence, we were not sur-
prised to observe general trends in the directions we had
foreseen, yet without individual miRNAs standing out as
‘the ultimate’ aging/frailty-related miRNA(s). What we
found is rather an intricate network of weakly acting
miRNAs; in fact each of the 9 miRNAs from our ‘aging
miRNA panel’ somehow showed significant, or at least
borderline, association(s) with one or more of the bio-
logical and/or clinical aging/frailty markers we previ-
ously evaluated [24], indicating that our ‘aging miRNA’
panel indeed consists of miRNAs that are truly relevant
in the context of the aging process.
Of course, as stated previously, this study has its limi-
tations due to the intrinsic peculiarities and heterogen-
eity of this particular oncogeriatric population, and
should be considered as a starting point towards a thor-
ough understanding of the complex relationships be-
tween cancer, aging and chemotherapy.
Conclusion
In conclusion, the uppermost result of this study is the
absence of any difference in the serum aging miRNA
profile between chemotherapy-treated and control pa-
tients during and after adjuvant chemotherapy. This
confirms our earlier findings with regard to the lack of a
major impact of chemotherapy on a variety of biological
and clinical aging markers.
Moreover, we created a miRNA-based clustering
model resulting into two distinct groups exhibiting sig-
nificantly different results for several biological/clinical
aging parameters.
Although this is only a beginning, gaining knowledge
about the interaction between the aging process and
cancer treatment is a crucial step in the process of tailor-
ing our treatments to older patients.
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